cell-free_dna_for_glioblastoma

Cell-free DNA for glioblastoma

Liquid biopsy can be used to detect recurrent disease, often earlier than using imaging modalities. Liquid biopsy is a rapidly developing field, and similarly to other types of cancer, measuring circulating tumor-derived nucleic acids from biological fluid samples could be the future of differential diagnostics, patient stratification, and follow up in the future in glioblastoma as well 1).


A number of circulating factors have been examined, including circulating tumor cells, cell-free DNA, microRNA, exosomes, and proteins from both peripheral blood and cerebrospinal fluid with variable results 2).


It was feasible to measure Cell-free DNA concentration. Despite the limited cohort size, there was a good tendency between cfDNA and treatment course and -response, respectively with the highest levels at progression 3)


Plasma cell-free DNA may be an effective prognostic tool and surrogate of tumor burden in newly diagnosed glioblastoma. Detection of somatic alterations in plasma is feasible when samples are obtained prior to initial surgical resection 4).


It is a promising prognostic biomarker for IDH wild-type glioblastoma. Plasma cfDNA can be obtained noninvasively and may enable more accurate estimates of survival and effective clinical trial stratification 5)


1)
Birkó Z, Nagy B, Klekner Á, Virga J. Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy. Int J Mol Sci. 2020 Oct 12;21(20):7522. doi: 10.3390/ijms21207522. PMID: 33053907; PMCID: PMC7589793.
2)
Jones J, Nguyen H, Drummond K, Morokoff A. Circulating Biomarkers for Glioma: A Review. Neurosurgery. 2021 Feb 16;88(3):E221-E230. doi: 10.1093/neuros/nyaa540. PMID: 33442748.
3)
Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study. Oncotarget. 2019 Jul 8;10(43):4397-4406. doi: 10.18632/oncotarget.27030. PMID: 31320993; PMCID: PMC6633897.
4)
Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2020 Jan 15;26(2):397-407. doi: 10.1158/1078-0432.CCR-19-2533. Epub 2019 Oct 30. PMID: 31666247; PMCID: PMC6980766.
5)
Bagley SJ, Till J, Abdalla A, Sangha HK, Yee SS, Freedman J, Black TA, Hussain J, Binder ZA, Brem S, Desai AS, O'Rourke DM, Long Q, Nabavizadeh SA, Carpenter EL. Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma. Neurooncol Adv. 2021 Jan 16;3(1):vdab011. doi: 10.1093/noajnl/vdab011. PMID: 33615225; PMCID: PMC7883768.
  • cell-free_dna_for_glioblastoma.txt
  • Last modified: 2021/02/22 21:25
  • by administrador